Literature DB >> 194636

Health of the intensively treated hemophiliac, with special reference to abnormal liver chemistries and splenomegaly.

P H Levine, B A McVerry, B Attock, K M Dormandy.   

Abstract

Liver function abnormalities have been noted in intensively treated hemophiliacs, and have led to less aggressive application of pooled plasma products by some physicians. In a prospective study, liver function was abnormal in 68 of 98 hemophiliacs. The abnormalities of hepatic function tended to persist over a 1-yr study period. There was no correlation between these abnormalities and the age of the patient, the presence of hepatitis-associated antigen or antibody, the presence or absence of splenomegaly (which was found in 26 of 98 patients), the number of infusions of plasma products, the type of hemophilia, or the type of product infused. Titers of antibodies to cytomegalovirus were generally higher in hemophilic patients than in a control group of healthy volunteers. These abnormalities did not suggest that a less aggressive infusion regimen was indicated for the hemophiliac, but did suggest the need for careful long-term observation of such patients.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 194636

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

Review 1.  Extended-field isocentric irradiation for Hodgkin's disease.

Authors:  P P Kumar; R R Good; E O Jones; J E Somers; B E McAnulty; G F McCaul; S S Rogers; M A Reeves; C K Sanders
Journal:  J Natl Med Assoc       Date:  1987-09       Impact factor: 1.798

2.  Post-transfusion hepatitis.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1981-07-04

3.  Prevalence of antibodies against hepatitis C virus in Norwegians with congenital coagulation factor defects treated with plasma products from small pools.

Authors:  H Rollag; S A Evesen; S S Fröland; A Glomstein
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-08       Impact factor: 3.267

4.  Viral exposure and abnormal liver function in haemophilia.

Authors:  B A McVerry; M G Ross; W A Knowles; J Voke
Journal:  J Clin Pathol       Date:  1979-04       Impact factor: 3.411

5.  Fibronectin in blood products--an in vitro and in vivo study.

Authors:  J T Reilly; B A McVerry; M J Mackie
Journal:  J Clin Pathol       Date:  1983-12       Impact factor: 3.411

6.  Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection.

Authors:  G D Morse; A Portmore; J Olson; C Taylor; C Plank; R C Reichman
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

7.  Liver disease complicating severe haemophilia in childhood.

Authors:  K M McGrath; J S Lilleyman; D R Triger; J C Underwood
Journal:  Arch Dis Child       Date:  1980-07       Impact factor: 3.791

8.  Non-invasive investigation of liver disease in haemophilic patients.

Authors:  E J Miller; C A Lee; P Karayiannis; S J Hamilton-Dutoit; R Dick; H C Thomas; P B Kernoff
Journal:  J Clin Pathol       Date:  1988-10       Impact factor: 3.411

9.  Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients.

Authors:  G D Morse; A C Portmore; V Marder; C Plank; J Olson; C Taylor; W Bonnez; R C Reichman
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

10.  Suppression of hepatitis C virus (HCV) replication by hepatitis D virus (HDV) in HIV-infected hemophiliacs with chronic hepatitis B and C.

Authors:  M E Eyster; J C Sanders; M Battegay; A M Di Bisceglie
Journal:  Dig Dis Sci       Date:  1995-07       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.